Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials | Zendy

Brendon L. Neuen | Zendy; Megumi Oshima | Zendy; Rajiv Agarwal | Zendy; Clare Arnott | Zendy; David Z.I. Cherney | Zendy; Robert Edwards | Zendy; Anna Maria Langkilde | Zendy; Kenneth W. Mahaffey | Zendy; Darren K. McGuire | Zendy; Bruce Neal | Zendy; Vlado Perkovic | Zendy; Annpey Pong | Zendy; Marc S. Sabatine | Zendy; Itamar Raz | Zendy; Tadashi Toyama | Zendy; Christoph Wanner | Zendy; David C. Wheeler | Zendy; Stephen D. Wiviott | Zendy; Bernard Zinman | Zendy; Hiddo J.L. Heerspink | Zendy

Open Access

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials

Author(s) -

Brendon L. Neuen,

Megumi Oshima,

Rajiv Agarwal,

Clare Arnott,

David Z.I. Cherney,

Robert Edwards,

Anna Maria Langkilde,

Kenneth W. Mahaffey,

Darren K. McGuire,

Bruce Neal,

Vlado Perkovic,

Annpey Pong,

Marc S. Sabatine,

Itamar Raz,

Tadashi Toyama,

Christoph Wanner,

David C. Wheeler,

Stephen D. Wiviott,

Bernard Zinman,

Hiddo J.L. Heerspink

Publication year - 2022

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.121.057736

Subject(s) - medicine , type 2 diabetes , hyperkalemia , randomized controlled trial , meta analysis , diabetes mellitus , cotransporter , benzhydryl compounds , pharmacology , sodium , endocrinology , chemistry , organic chemistry , bisphenol a , epoxy

Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease. However, their effect on hyperkalemia has not been systematically evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research